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Early Stage Testicular Seminoma: 
A Multicenter Review of Treatment 
Outcomes and Patterns of Recurrence
Purpose/Objective(s)
Although overall survival for early stage testicular seminoma is 
generally excellent, certain pathologic factors can increase recurrence 
risk for those undergoing observation, while radiation therapy (RT) 
can be associated with long-term morbidity. We sought to identify 
disease-related and treatment-related factors that influenced the 
outcomes, with particular emphasis on recurrence risk, patterns and 
timing of recurrence, as well as RT-induced malignancy.
Material/Methods
With IRB approval, we identified and reviewed medical records 
of stage I or II testicular seminoma patients from two institutions 
(University of Pennsylvania and Thomas Jefferson University) who 
received adjuvant RT or observation between 1979-2009. Patient-, 
disease-, and treatment-related variables were obtained including 
age, history of undescended testicle, previous inguinal surgery, 
date of diagnosis, stage, tumor volume and characteristics, RT dose/
fractionation and volume, disease recurrence, and second malignancy.
Results
A total of 104 patients were identified: 92 with stage I disease and 12 
with stage II disease. Median age was 37 years and median follow-up 
was 3.2 years. Eighty-one stage I patients underwent adjuvant RT (88% 
of study population), while 11 underwent observation (12% of study 
population). All stage II patients were treated with adjuvant RT. Total 
RT dose ranged from 9-36 Gy (median = 26 Gy). Five patients (4 stage 
I, 1 stage II) experienced disease recurrence at a median of 1.7 years 
(4.8% of study population). Among stage I patients with recurrence, 
2 patients received RT (2.5% of treated population), while 2 patients 
were observed (18% of observed population). Local control with 
adjuvant RT was 100%, as all recurrences were systemic, outside of 
the RT field. Disease-related factors, such as largest tumor dimension, 
tumor size, lymphovascular invasion, rete testis and spermatic cord 
involvement, and preoperative laboratory markers (LDH, B-HCG) 
were not found to be significantly associated with recurrence risk. 
Three patients developed a second malignancy within the RT field 
(3.3% of treated population) at a median time of 14.6 years. All 3 
patients were treated with dogleg field to a median dose of 36 Gy.
Conclusion
Although early stage seminoma is associated with excellent long-
term results, our study suggests recurrence risk approaches 20% in 
patients undergoing observation. Routine follow-up regimens should 
be adhered to, especially in the first few years, as most recurrences 
occurred within 2 years of treatment. While rates of RT-induced 
malignancy were low, these rates may be further improved by 
minimizing RT dose and volume.
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